NRX Pharmaceuticals Inc (NRXP) Financials

$3.46

$0.02 (0.58%)

As on 02-Sep-2026 16:00EDT

Market cap

$154 Mln

Revenue (TTM)

$3 Mln

P/E Ratio

--

P/B Ratio

2.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	3.39	1.23	--	--	--	--
Cost of Revenue	2.29	0.51	0.01	0.01	0.00	0.00
Gross Profit	1.11	0.72	-0.01	-0.01	0.00	0.00
Operating Expenses	21.07	16.94	19.70	27.58	44.33	95.20
Operating Profit (EBIT)	-19.97	-16.22	-19.70	-27.59	-44.34	-95.20
Other Income	--	--	--	--	--	--
Profit before Tax	-23.48	-28.62	-25.13	-30.15	-39.75	-93.06
Provision for Tax	--	--	--	-0.01	-4.58	-21.35
Profit after Tax (Net Income)	-23.48	-28.62	-25.13	-30.15	-39.75	-93.06
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-39.75	-348.89

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-0.17	-15.94	-23.22	-11.73	7.41	20.81
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.46	0.32	5.01	--	2.82	4.21
Current Liabilities	33.87	28.58	21.86	19.05	15.59	11.92
Total Liabilities	68.03	12.96	3.65	7.32	25.82	32.73

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	5.00	4.06	0.35	0.43	0.02	0.02
Current Assets	29.16	8.89	3.30	6.88	25.80	32.71
Total Assets	63.32	12.96	3.65	7.32	25.82	32.73
Total Debt*	1.25	0.63	6.58	9.16	10.53	0.52
Net Current Assets	--	-19.69	-18.56	-12.16	10.21	20.79

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-14.11	-10.64	-21.66	-39.76	-37.70
Cash Flow from Investing Activities	--	-2.81	--	0.00	-0.01	-0.01
Cash from Financing Activities	--	23.28	7.49	6.20	32.21	63.46
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.74	-0.90	-2.39	-0.36	-0.60	-1.80
Cash EPS ($)	--	-0.90	-2.39	-0.36	-0.60	-1.80
Adjusted Book Value ($)	--	--	--	--	0.11	0.40
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.44	-1.01	-0.26	-0.60	-0.73
Free Cash Flow per Share ($)	--	-0.44	-1.01	-0.26	-0.60	-0.73

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	179.16	261.48	-392.53	-202.53	859.70
ROE (%)	--	146.18	143.76	1,394.54	-281.79	810.48
ROA (%)	-43.24	-344.70	-458.25	-182.00	-135.81	-521.80
EBIT Margin (%)	-658.10	-2,281.71	--	--	--	--
Net Margin (%)	-691.81	-2,336.49	--	--	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	42,325.00	--	--	--	--	--
EBIT Growth (%)	-12.00	-16.23	19.92	24.46	57.27	-79.90
Net Profit Growth (%)	30.52	-13.91	16.66	24.16	57.28	-79.74
EPS Growth (%)	68.35	0.62	-5.65	0.40	0.67	0.77
Book Value Growth (%)	99.77	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-3.00	-0.92	-1.28	-1.86	-2.66
Price / Book Value	2.90	-5.40	-1.00	-3.29	9.96	11.89
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.15	-2.83	-1.18	-1.44	-1.62	-2.37
Close Price ($)	4.09	2.71	2.20	4.60	11.10	47.80
High Price ($)	5.06	6.01	7.33	14.10	51.50	642.00
Low Price ($)	1.62	1.58	1.10	2.21	4.90	40.70
Market Cap ($ Cr)	153.70	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	-0.04	-0.28	-0.78	1.42	0.02
Short term debt to equity ratio	-4.65	-0.02	-0.07	-0.78	1.04	0.02
Current Ratio	0.86	0.31	0.15	0.36	1.66	2.74
Quick Ratio	0.86	--	--	0.36	1.66	--
Interest Coverage	-19.52	-41.66	-22.29	-250.25	-8.68	-5,169.17

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	6.07	13.14	--	--	--	--
Asset Turnover	0.06	0.15	--	--	--	--
Receivable days	--	24.00	--	--	--	--
Inventory Days	--	--	-438.30	-474.83	-639.19	39,081.75
Payable days	--	3,037.72	320,032.05	245,009.70	263,116.97	624,577.50
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.